Emerald Acquisition Ltd. purchased a new stake in Safeguard Scientifics Inc. (NYSE:SFE) during the second quarter, according to its most recent filing with the SEC. The fund purchased 49,299 shares of the company’s stock, valued at approximately $616,000. Emerald Acquisition Ltd. owned approximately 0.24% of Safeguard Scientifics at the end of the most recent reporting period.
Several other institutional investors have also bought and sold shares of the company. First Manhattan Co. increased its position in Safeguard Scientifics by 0.5% in the second quarter. First Manhattan Co. now owns 1,693,363 shares of the company’s stock valued at $21,150,000 after buying an additional 8,605 shares in the last quarter. Yakira Capital Management Inc. increased its position in Safeguard Scientifics by 14.3% in the first quarter. Yakira Capital Management Inc. now owns 487,645 shares of the company’s stock valued at $6,461,000 after buying an additional 60,823 shares in the last quarter. Bank of Montreal Can acquired a new position in Safeguard Scientifics during the second quarter valued at $5,664,000. American Research & Management Co. increased its position in Safeguard Scientifics by 13.3% in the second quarter. American Research & Management Co. now owns 170,866 shares of the company’s stock valued at $2,134,000 after buying an additional 20,100 shares in the last quarter. Finally, Foundry Partners LLC increased its position in Safeguard Scientifics by 0.3% in the second quarter. Foundry Partners LLC now owns 166,794 shares of the company’s stock valued at $2,083,000 after buying an additional 475 shares in the last quarter. 78.62% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Safeguard Scientifics Inc. (NYSE:SFE) traded down 0.23% during trading on Friday, reaching $12.95. 21,727 shares of the company’s stock were exchanged. Safeguard Scientifics Inc. has a 52 week low of $11.40 and a 52 week high of $18.07. The stock’s market capitalization is $261.90 million. The stock has a 50 day moving average price of $13.34 and a 200-day moving average price of $13.32.
Safeguard Scientifics (NYSE:SFE) last announced its quarterly earnings data on Thursday, July 28th. The company reported $1.92 EPS for the quarter, topping the Zacks’ consensus estimate of $1.47 by $0.45. During the same quarter in the previous year, the company posted ($0.91) EPS. Analysts predict that Safeguard Scientifics Inc. will post $0.24 earnings per share for the current year.
Separately, Zacks Investment Research raised shares of Safeguard Scientifics from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a research note on Wednesday.
In related news, CEO Stephen T. Zarrilli purchased 3,900 shares of the stock in a transaction dated Wednesday, September 14th. The shares were acquired at an average cost of $12.75 per share, with a total value of $49,725.00. Following the purchase, the chief executive officer now directly owns 103,606 shares in the company, valued at approximately $1,320,976.50. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 2.67% of the company’s stock.
Safeguard Scientifics Company Profile
Safeguard Scientifics, Inc provides capital, as well as strategic, operational and management resources to growth-stage businesses. The Company participates in early- and growth-stage financings. The Company operates through two segments: Healthcare and Technology. The Healthcare segment’s companies focuses principally on medical technology (MedTech), including diagnostics and devices, and healthcare technology (HealthTech).
Want to see what other hedge funds are holding SFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Safeguard Scientifics Inc. (NYSE:SFE).
Receive News & Ratings for Safeguard Scientifics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Safeguard Scientifics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.